BCL2 and neuroblastoma: These findings are consistent with another pan-cancer study demonstrating that many NE and hematological cancers (YAPoff cancers) share vulnerabilities to HDAC, BCL2, and NAMPT inhibitors [69], as well as work showing that NE subsets of SCLC and neuroblastoma are more sensitive to BCL2 inhibitors [89].